FY2020 EPS Estimates for Collegium Pharmaceutical, Inc. Lifted by Gabelli (COLL)

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) – Equities researchers at Gabelli increased their FY2020 earnings per share estimates for shares of Collegium Pharmaceutical in a note issued to investors on Thursday. Gabelli analyst K. Kedra now expects that the specialty pharmaceutical company will post earnings of $0.50 per share for the year, up from their previous forecast of $0.45. Gabelli also issued estimates for Collegium Pharmaceutical’s FY2021 earnings at $1.70 EPS.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.81) by $0.09. The firm had revenue of $3.56 million during the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%.

WARNING: “FY2020 EPS Estimates for Collegium Pharmaceutical, Inc. Lifted by Gabelli (COLL)” was posted by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thestockobserver.com/2017/08/12/fy2020-eps-estimates-for-collegium-pharmaceutical-inc-lifted-by-gabelli-coll.html.

COLL has been the subject of several other reports. Piper Jaffray Companies set a $14.00 price objective on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Tuesday, July 25th. Needham & Company LLC reissued a “buy” rating and set a $25.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, May 31st. ValuEngine raised Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Thursday, June 22nd. Zacks Investment Research lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Wednesday, May 10th. Finally, BidaskClub lowered Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. Three investment analysts have rated the stock with a sell rating and five have assigned a buy rating to the stock. Collegium Pharmaceutical currently has a consensus rating of “Hold” and a consensus target price of $21.33.

Collegium Pharmaceutical (NASDAQ:COLL) traded up 3.19% during mid-day trading on Friday, reaching $10.34. The company had a trading volume of 460,789 shares. Collegium Pharmaceutical has a 1-year low of $7.37 and a 1-year high of $20.55. The firm has a 50-day moving average of $12.14 and a 200 day moving average of $11.95. The company’s market capitalization is $305.71 million.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Macquarie Group Ltd. acquired a new position in shares of Collegium Pharmaceutical during the fourth quarter valued at $127,000. American International Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after buying an additional 2,163 shares in the last quarter. Nationwide Fund Advisors boosted its stake in shares of Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares in the last quarter. Credit Suisse AG boosted its stake in shares of Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares in the last quarter. Finally, UBS Group AG boosted its stake in shares of Collegium Pharmaceutical by 283.2% in the first quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after buying an additional 10,174 shares in the last quarter. Hedge funds and other institutional investors own 82.27% of the company’s stock.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Earnings History and Estimates for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply